Why You're Hitting a Plateau on Wegovy (and What the Evidence Says)

What the STEP 1 trial data actually show about slowing weight loss

The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults on semaglutide 2.4 mg over 68 weeks. Average weight loss reached around 15% of body weight, but the reduction was front-loaded: the sharpest drop came in the first six months, with the curve flattening noticeably in the final quarter of the study. This is not a quirk of the trial design. It reflects something reliable and biological. When body weight falls, energy expenditure falls with it — a smaller body burns fewer calories at rest. At the same time, appetite-suppressing signals from GLP-1 receptor activation become part of the body's new normal, which blunts some of the acute appetite reduction that made early weeks feel so different. The result is a genuine metabolic adaptation, not a failure of the medicine to work. Understanding this distinction matters, because the instinct to assume something has gone wrong (and to look for a quick fix) can lead people to make changes that are not clinically indicated. If you want a clearer sense of what Wegovy typically delivers in the first three months, that context helps frame where a wegovy plateau sits in the overall timeline.

Why a plateau does not always mean the dose needs to change

The most common prescriber question at a plateau is whether the current dose is doing its job or whether a step-up is warranted. The answer depends on where in the titration schedule the person sits. Wegovy's licensed schedule runs from 0.25 mg through to the 2.4 mg maintenance dose, titrated roughly every four weeks by the prescriber; the MHRA-approved 7.2 mg pen offers a higher ceiling for eligible patients. For someone already at maintenance, an increase is not automatically available, and the NICE appraisal of semaglutide (TA875) notes that treatment should be reviewed if less than 5% of body weight has been lost after six months at the maintenance dose, not after six weeks of slower progress. A plateau at week ten is different from a plateau at month eight. The clinical question is whether the medicine is still delivering meaningful weight loss over a longer window, not whether the scales moved this week. Reviewing how long Wegovy takes to work across the full course can give a more grounded benchmark than week-to-week comparisons.

There is also a practical factor that often goes unacknowledged. Caloric drift is well-documented in weight-loss research: as appetite suppression becomes familiar, portion sizes can creep back up without the person noticing. The medicine reduces hunger; it does not override every food decision. A prescriber-led review of dietary patterns (not a dramatic cut, but an honest audit) is often enough to break a true stall.

Lifestyle factors that independently affect whether a plateau resolves

Several variables sit outside the medicine's direct control. Protein adequacy is one. When calorie intake falls sharply, the body can draw on lean mass as well as fat; preserving muscle through adequate protein (and resistance exercise where possible) keeps metabolic rate higher than it would otherwise be, which directly affects whether a plateau tips into resumed loss or stays fixed. Sleep is another: poor sleep raises cortisol and disrupts appetite hormones independently of GLP-1 activity, which can blunt the medicine's effect. Neither of these requires a prescription change to address. The NHS Better Health guidance on healthy weight covers the lifestyle foundations that work alongside medical treatment; they are worth revisiting during a plateau rather than waiting for the medicine to do all the work. One thing our prescribers hear regularly: people notice plateaus more acutely around months where life gets busier, school holidays, a run of long working weeks, the period after a bank holiday when routine goes sideways. That disruption to eating and activity patterns is often the real driver, not a change in the medicine's efficacy, and our guide on plateauing on Wegovy goes into more detail on how to work through those circumstances. Reviewing what has shifted in daily life is a practical first question before concluding the treatment has stopped working. If you are weighing up what Wegovy costs as a private prescription, understanding the full timeline also helps assess whether the treatment is delivering value over the months expected.

When to raise a plateau with your prescriber

A plateau lasting two to three weeks during active titration is almost always metabolic adaptation and resolves without intervention. A plateau lasting six to eight weeks at maintenance dose, with no change in lifestyle circumstances, is worth raising at your next clinical review. Red flags that warrant earlier contact include unexplained weight gain rather than a simple stall, new symptoms that might be affecting appetite or energy, or any concern that the medicine has genuinely stopped working. At nume, clinical review happens before every repeat order, a prescriber reads the case, not a dashboard. That review is the right moment to raise a plateau formally: it can trigger a dose discussion, a referral for dietary advice, or a review of whether the current treatment is still the right fit. You can explore your options, including how plateaus are handled in the clinical pathway, on the Wegovy overview page or by speaking to the team directly via our contact page. If you are at the point of wanting to review your treatment from the beginning, start a free consultation and a prescriber will assess the full picture the same day.